Abstract
Head and neck cancer is a term that encompasses heterogeneous types of malignant tumors occurring in heterogeneous groups of patients. Histologically, squamous cell carcinoma is the most common type. Because of this heterogeneity, the natural history, disease-free survival, overall survival, and the local and regional failure may vary from one report to another.
Keywords
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Amer MH, Izbicki RM, Vaitkevicius VK, Al-Sarraf M: Combination chemotherapy with cis-diamminedichloroplatinum, Oncovin and bleomycin (COB) in advanced head and neck cancers: phase II. Cancer 45:217–233, 1980.
Kish JA, Drelichman A, Weaver A, et al.: Cis-platinum and 5-fluorouracil infusion in patients with recurrent and disseminated epidermoid cancer of the head and neck. Proc ASCO 1:193, 1982.
Kish JA, Weaver A, Jacobs J, et al.: Cis-platinum and 5-fluorouracil infusion in patients with recurrent and disseminated epidermoid cancer of the head and neck. Cancer 53:1819–1824, 1984.
Drelichman A, Cummings G, Al-Sarraf M: A randomized trial of the combination of cis-platinum, Oncovin and bleomycin (COB) vs. methotrexate in patients with advanced squamous cancer of the head and neck. Cancer 52:399–403, 1983.
De Conti R.C, Schoenfeld D: A randomized prospective comparison of intermittent methotrexate, methotrexate with leucovorin and a methotrexate combination in head and neck cancer. Cancer 48:1061–1072, 1981.
Amer MH, Al-Sarraf M, Vaitkevicius VK: Factors that effect response to chemotherapy and survival of patients with advanced head and neck cancer. Cancer 43:2202–2206, 1979.
Amrein PC, Fingert H, Weitzman SA: Cis-platin-vincristine-bleomycin therapy in squamous cell carcinoma of the head and neck. J Clin Oncol 1:421–427, 1983.
Al-Sarraf M: The cost and clinical value of combination of cis-platinum, Oncovin and bleomycin (COB) vs. methotrexate in patients with advanced head and neck epidermoid cancer. Proc ASCO 21:354, 1980.
Bell R, Sullivan JR, Fleming WG, Grey PA, Miller HS: Results of treatment of head and neck carcinoma with high dose methotrexate. Clin Exp Pharmacol Physiol [Suppl] 5:22, 1979.
Capizzi RL, De Conti RC, Marsh JC, Bertino JR: Methotrexate therapy of head and neck cancer: improvement in therapeutic index by the use of the leucovorin rescue. Cancer Res 30:1782–1788, 1970.
Frei E III, Blum RH, Pitman SW, et al.: High dose methotrexate with leucovorin rescue: rationale and spectrum of antitumor activity. Am J Med 68:370–376, 1973.
Hong WK, Schaefer S, Issell B, et al.: A prospective randomized trial of methotrexate versus cis-platinum in the treatment of recurrent squamous cell carcinoma of the head and neck. Cancer 52:206–210, 1983.
Kaplan BH, Schoenfeld D, Vogl S: Treatment of recurrent or metastatic squamous cancer of the head and neck with methotrexate (M) plus Coryneb acterium parvum, or M plus bleomycin plus diamminedichloroplatinum: a prospective randomized trial of the Eastern Cooperative Oncology Group. Proc AACR 22:532, 1981.
Kirkwood JM, Canellos GP, Ervin TJ, et al.: Increased therapeutic index using moderate dose methotrexate-leucovorin in patients with advanced squamous carcinoma of the head and neck: a safe new effective regimen. Cancer 47: 2414–2421, 1981.
Lehane DE, Lane M, Stucky WJ: A comparison of methotrexate (M) with methyl CCNU (MC) and bleomycin (B) in patients with advanced squamous cell carcinoma of the head and neck (H&N) region: a southwest Oncology Group Study. Proc ASCO 21:331, 1980.
Lane M, Moore JL III, Levin H, Smith FE: Methotrexate therapy for squamous cell carcinoma of the head and neck. JAMA 204:561–564, 1968.
Leone LA, Albala MM, Rage VB: Treatment of carcinoma of the head and neck with intravenous methotrexate. Cancer 21:828–837, 1968.
Mitchell MS, Wawro NW, De Conti RC, et al.: Effectiveness of high dose infusions of methotrexate followed by leucovorin in carcinoma of the head and neck. Cancer Res 28:1088–1094, 1968.
Papac RJ, Lefkowitz E, Bertino JR: Methotrexate (NSC-740) in squamous cell carcinoma of the head and neck. II. Intermittent intravenous therapy. Cancer Chemother Rep 51:69–72, 1967.
Priestman TJ: Results in fifty cases of advanced squamous cell carcinoma of the head and neck treated by intravenous chemotherapy. Br J Cancer 27:400–405, 1973.
Vogler WR, Jacobs J, Moffitt S, et al.: Methotrexate therapy with or without citrovor-um factor in carcinoma of the head and neck, breast, and colon. Cancer Clin Trials 2:227–236, 1979.
Williams SD, Einhorn LH, Velez-Garcia E, et al.: Chemotherapy of head and neck cancer: comparison of cis-platinum + vinblastine + bleomycin (PVB) versus methotrexate. Proc ASCO 1:202, 1982.
Woods RL, Fox RM, Tattersall MHN: Methotrexate treatment of squamous cell head and neck cancers: dose response evaluations. Br Med J 282:600–602, 1981.
Bonadonna G, De Lana M, Monfardini S, et al.: Clinical trials with bleomycin in lymphomas and in solid tumors. Eur J Cancer 8:205–215, 1972.
Durkin WJ, Pugh RP, Jacobs E, et al.: Bleomycin (NSC-125066) therapy of responsive solid tumors. Oncology 33:260–264, 1976.
Clinical Screening Cooperative Group of the European Organization for Reserach on Treatment of Cancer: Study of the clinical efficiency of bleomycin in human cancer. Br Med J 2:643, 1970.
Haas CD, Coltman CA Jr, Gottlieb JA, et al.: Phase II evaluation of bleomycin: a Southwest Oncology Group Study. Cancer 38:8–12, 1976.
Hainan KE, Bleehen NM, Brewin TB, et al.: Early clinical experience with bleomycin in the United Kingdom in a series of 105 patients. Br Med J 4:635–638, 1972.
Yagoda A, Mukherji B, Young C, et al.: Bleomycin: an antitumor antibiotic clinical experience in 274 patients. Ann Intern Med 77: 861–870, 1972.
Hayat M, Bayssas M, Brule G, et al.: Cis-dichlorodiammineplatinum (CDDP) in chemotherapy of cancer. Biocheme 60:935–940, 1978.
Hill JM, Loeb E, Maclellan A, et al.: Clinical studies of platinum coordination compounds in the treatment of various malignant diseases. Cancer Chemother Rep 59:647–649, 1975.
Jacobs C, Bertino JR, Goffinet DR, et al.: 24-hour infusion of cis-platinum in head and neck cancer. Cancer 42:2135–2140, 1978.
Panettiere FJ, Lehane D, Fletcher WJ, et al.: Cis-platinum therapy of previously treated head and neck cancer: the Southwest Oncology Group two-dose-per-month outpatient regimen. Med Pediatr Oncol 8:221–225, 1980.
Randolph VL, Wittes RE: Weekly administration of cisdiamminedichloroplatinum (II) without hydration or osmotic diuresis. Eur J Cancer 14:753–756, 1978.
Sako, Razack MS, Kalnins I: Chemotherapy for advanced and recurrent squamous cell carcinoma of the head and neck with high and low dose cis-diamminedichloroplatinum. Am J Surg 136:529–533, 1978.
Stephens R, Coltman C, Rossof A, et al.: Cis-dichlorodiammineplatinum (II) in adult patients: Southwest Oncology Group Studies. Cancer Treat Rep 63:1609–1610, 1979.
Wittes RE, Cvitkovic E, Shah J, et al.: Cis-dichlorodiammineplatinum (II) in the treatment of epidermoid carcinoma of the head and neck. Cancer Treat Rep 61:359–366, 1977.
Wittes R, Heller K, Randolph V, et al.: Cis-dichlorodiammineplatinum (II) based chemotherapy as initial treatment of advanced head and neck cancer. Cancer Treat Rep 63:1533–1538, 1970.
Wittes RE: Chemotherapy of head and neck cancer. Otolaryngol Clin North Am 13:515–520, 1980.
Rozencweig M, Slavik M, Muggia FM, Carter SK: Overview of early and investigational che-motherapeutic agents in solid tumors. Med Pediatr Oncol 2:417–432, 1976.
Rozencweig M, Von Hoff DD, Muggia FM: Investigational chemotherapeutic agents in head and neck cancer. Semin Oncol 4:425–429, 1977.
Boccardo F, Barbieri A, Canobbio L, et al.: Phase II trial of thioproline in advanced epidermoid head and neck tumors. Cancer Treat Rep 66:585–586, 1982.
Campbell M, Al-Sarraf M: Phase II Ftorafur therapy in previously treated squamous cell cancer of the head and neck. Cancer Treat Rep 64:713–715, 1981.
Chapman R, Kelson D, Gralla R: Phase II trials of methylglyoxal bis (guanylhydrazone) (MGBG) in three solid tumors. Proc ASCO 22: 526, 1981.
Creagan ET, Nichols WS, O’Fallen JR: Phase II evaluation of PALA in patients with advanced head and neck cancer. Cancer Treat Rep 65:827–829, 1981.
Creagan ET, Fleming TR, Edmonson JH, Ingle JN: Phase II evaluation of maytansine in patients with advanced head and neck cancer. Cancer Treat Rep 63:2061–2062, 1979.
Forastiere AA, Crain SM, Callahan K, Van Echo D, Mattox D, Thant M, Van Hoff DD, Wiernik PH: Phase II trial of aziridnylbenzo-quinone (AZQ) in head and neck cancer. Cancer Treat Rep 66:2097–2098, 1982.
Kish JA, Al-Sarraf M: Unpublished data.
Kish J A, Al-Sarraf M: Aclacinomycin: phase II evaluation in advanced squamous carcinoma of the head and neck. Am J Clin Oncol (in press).
Papac RJ, Fischer JJ: Cytosine arabinoside (NSC 63878) in the treatment of epidermoid carcinomas of the head and neck. Cancer Chemother Rep 55:193–197, 1971.
Perry DJ, Crain SM, Weltz MD, Wilson JP, Davis RK, Wooley PV, Forastiere AA, Taylor MG, Weiss RB: Phase II trial of mitoguanzone in patients with advanced squamous cell carcinoma of the head and neck. Cancer Treat Rep 67:91–92, 1983.
Ratanatharathorn V, Drelichman A, Sexton-Porte M, Al-Sarraf M: Phase II evaluation of 4’-(9-acridinylamino)-methanesulfon-m-anisidine (AMSA) in patients with advanced head and neck cancers. Am J clin Oncol 5:29–32, 1982.
Shah MK, Engstrom PE, Catalano RB, et al.: Phase II trial of Razoxan (ICRF-159) in patients with squamous cell carcinoma of the head and neck previously exposed to systemic chemotherapy. Cancer Treat Rep 66:557–558, 1982.
Amer MH: Combination chemotherapy (COB) for advanced squamous cell carcinoma of the head and neck with Cytoxan (CTS), vincristine (VCR) and bleomycin (BLM). Proc ASCO 21:474, 1980.
Bianco AA, Taylor SG IV, Reich SD, et al.: Combination chemotherapy in head and neck squamous cancer. Proc ASCO 19:380, 1978.
Cortes EP, Kalra J, James R, et al.: Chemotherapy for head and neck cancer in relapse after prior radiotherapy and evaluation of method of bleomycin (Bleo) administration anti-tumor effect. Proc ASCO 21:364, 1980.
Didolkar MS, Coleman JJ, Elias EG, et al.: Chemotherapy for advanced carcinoma of head and neck: an effective out patient schedule of Cytoxan, Oncovin, methotrexate, and bleomycin. Head Neck Surg 4:92–97, 1981.
Fazio M, Cavallero P, Minetto E, et al.: Polychemotherapy of advanced head and neck malignancies. Tumor 62:599–608, 1976.
Holoye PY, Byers RM, Gard DA, et al.: Combination chemotherapy of head and neck cancer. Cancer 42:1661–1669, 1978.
Lester EP, Kinnealey A, Matz GJ: Sequential combination chemotherapy for advanced squamous cell carcinoma of the head and neck. Laryngoscope 89:1921–1929, 1979.
Livingston RB, Einhorn LH, Burgess MA, Gottlieb JA: Sequential combination chemotherapy for advanced recurrent squamous carcinoma of the head and neck. Cancer Treat Rep 60:103–105, 1976.
Perry MC, Davidson EM, Kardinal CG: Chemotherapy of recurrent squamous cell carcinoma of the head and neck. Proc ASCO 21:479, 1980.
Presant CA, Ratkin G, Klahr L, Brown C: Adriamycin, BCNU plus cyclophosphamide (ABC) in advanced carcinoma of the head and neck. Cancer 44:1571–1575, 1979.
Stathopoulos G, Wiltsaw E, Price LA: Quadruple chemotherapy in advanced squamous cell carcinoma of the head and neck. Br J Clin Pract 30:188–189, 1976.
Wittes RE, Spiro RH, Shah J, et al.: Chemotherapy of head and neck cancer: combination treatment with cyclophosphamide, adriamycin, methotrexate and bleomycin. Med Pediatr Oncol 3:301–309, 1977.
Miyamoto T: A sequential combination of bleomycin and mitomycin-C in the treatment of advanced squamous cancers. Recent Results Cancer Res 63:179–190, 1978.
Wheeler RH, Liepman MK, Baker SR, et al.: Bleomycin, vincristine, and mitomycin-C with or without methotrexate in the treatment of squamous cell carcinoma. Cancer Treat Rep 64:943–949, 1980.
Huang AT, Lucas VS, Baughn SG, Cole TB: A trial of outpatient chemotherapy for recurrent head and neck tumors. Cancer 45:2038–2041, 1982.
Richman SP, Livingston RB, Gutterman JK, et al.: Chemotherapy versus chemoimmuno-therapy of head and neck cancer: report of a randomized study. Cancer Treat Rep 60:535–539, 1976.
Brown AW Jr, Blom J, Butler WM, et al.: Combination chemotherapy with vinblastine, bleomycin and cis-diamminedichloroplatinum (II) in squamous cell carcinoma of the head and neck. Cancer 45:2830–2835, 1980.
Caradonna R, Paladine W, Ruckdeschel JC, et al.: Methotrexate, bleomycin and high-dose cis-diamminedichloroplatinum (II) in the treatment of advanced epidermoid carcinoma of the head and neck. Cancer Treat Rep 63:489–491, 1979.
Creagan ET, Fleming TR, Edmonson JH, et al.: Cyclophosphamide, adriamycin and cis-diamminedichloroplatinum (II) in the treatment of patients with advaned head and neck cancer. Cancer 47:240–244, 1981.
Creagan ET, Fleming TR, Edmonson JH, et al.: Chemotherapy for advanced head and neck cancer with combination adriamycin, cyclophosphamide and cis-diamminedichloroplatinum (II): preliminary assessment of a one-day vs. three-day regimen. Cancer 47: 2549–2551, 1981.
Elias EG, Chretien PB, Monnard E, et al.: Chemotherapy prior to local therapy in advanced squamous cell cancer of the head and neck: preliminary assessment of an intensive drug regimen. Cancer 43:1025–1031, 1979.
Ervin TJ, Weichselbaum R, Miller D, et al.: Treatment of advanced squamous cell carcinoma of the head and neck with cis-platinum, bleomycin and methotrexate (PBM). Cancer Treat Rep 65:787–791, 1981.
Jacobs C: High dose methotrexate and cis-platinum in the treatment of recurrent head and neck cancer. Recent Results Cancer Res 76: 290, 1979.
Jakse R, Lehnert M, Scherlacher A: Palliative chemotherapy of recurring squamous cell carcinomas of head and neck with the combination of cis-diamminedichloroplatinum (II) (DDP)/ adriamycin (ADM). Laryngol Rhinol Otol 61:524–528, 1981.
King GW, Halpin JJ, Smith RE, et al.: Cis-dichlorodiammineplatinum (II), methotrexate, bleomycin and vincristine in head and neck cancer: a pilot study. Cancer Treat Rep 63: 1735–1738, 1979.
Kaplan BH, Vogl SE, Chiuten D, et al.: Chemotherapy of advanced cancer of the head and neck (HNCa) with methotrexate (M), bleomycin (B) and cis-diamminedichloroplatinum (D) in combination “MBD.” Proc ASCO 20:384.
Kuten A, Zidan J, Cohen Y, Robinson E: Multi-drug chemotherapy using bleomycin, methotrexate and cis-platinum alone or combined with radiotherapy in advanced head and neck cancer. Cancer Treat Rep 67:573–574, 1983.
Murphy WK, Valdivieso M, Bodey GP, Freireich EG: Cis-dichlorodiammineplatinum (DDP), methotrexate (MTX) and bleomycin (BLM) chemotherapy for patients with advanced squamous cell carcinoma (SCC) of the head and neck (H&N). Proc AACR 21:166.
Perry DJ, Weltz MD, Brown AWJ, Henderson RL, Neglia WJ, Berenbert JL: Vinblastine, bleomycin and cis-platinum for recurrent or metastatic squamous cell carcinoma of the head and neck. Cancer 50:2257–2260, 1982.
Vogl SE, Kaplan BH: Chemotherapy of advanced head and neck cancer with methotrexate, bleomycin and cis-diamminedichloroplatinum II in an effective outpatient schedule. Cancer 44:26–31, 1979.
Vogl SE, Lerner H, Kaplan BM, et al.: Mitomycin-C, methotrexate, bleomycin and cis-diamminedichloroplatinum II in the chemotherapy of advanced squamous cell cancer of the head and neck. Cancer 50:6–9, 1982.
Von Hoff D, Alberts D, Mattox D, et al.: Combination chemotherapy with cis-platinum, bleomycin and methotrexate in patients with advanced head and neck cancer. Cancer Clin Trials 4:215–218, 1981.
Wittes RE, Brescia F, Young EW, et al.: Combination chemotherapy with cis-diamminedichloroplatinum (II) and bleomycin in tumors of the head and neck. Oncology 32: 202–207, 1975.
Costanzi JJ, Loukas D, Gagliano RG, et al.: Intravenous bleomycin infusion as a potential synchronizing agent in human disseminated malignancies: a preliminary report. Cancer 38:1503–1506, 1976.
Eisenberger M, Denefrio JM, Kaplan DL, et al.: Combination chemotherapy with bleomycin (Bleo) and hydroxyurea (HU) in the treatment of advanced head and neck cancer. Proc ASCO 21:343, 1980.
Jacobs C: Use of methotrexate and 5-FU for recurrent head and neck cancer. Cancer Treat Rep 66:1925–1928, 1982.
Pitman SW, Kowal CD, Papac RJ, Bertino JR: Sequential methotrexate-5-fluorouracil: a high active drug combination in advance squamous cell carcinoma of the head and neck. Presented at the international head and neck oncology ressearch conference, September 1980. Proc AACR-ASCO 21:473, 1980.
Raafat J, Oster MW: Combination chemotherapy for advanced squamous cell carcinoma of the head and neck. Cancer Treat Rep 64:187–189, 1980.
Price LA, Hill BT, Calvert AH, et al.: Improved results in combination chemotherapy of head and neck cancer using a kinetically based approach: a randomized study with and without adriamycin. Oncology 35:26–28, 1978.
Ringborg U, Ewert G, Kinnman J, et al.: Sequential methotrexate-5-flurorouracil treatment of squamous cell carcinoma of the head and neck. Cancer 52:971–973, 1983.
Thatcher N, Blackledge G, Crowther D: Advanced recurrent squamous cell carcinoma of the head and neck: results of a chemotherapeutic regimen with adriamycin, bleomycin, 5-fluorouracil, methotrexate and vitamin A. Cancer 46:1324–1328, 1980.
Woods RL, Stewart J, Fox RM, Tattersol MNH: Combination chemotherapy with vincristine, bleomycin and methotrexate for advanced head and neck cancer. Cancer Treat Rep 63:1997–1999, 1979.
Yagoda A, Lippman AJ, Winn RJ, et al.: Combination chemotherapy with bleomycin and methotrexate in patients with advanced epidermoid cancer. Proc ASCO 16:247, 1975.
Kish J, Decker D, Bergsman K, Al-Sarraf M: Preliminary reports of treatment of recurrent squamous carcinoma of the head and neck with cis-platinum (CACP) 4–5FU infusion vs. CACP + 5FU bolus. Proc ASCO 2:163, 1983.
Donaldson RC: Chemoimmunotherapy for cancer of the head and neck. Am J Surg 126:507–512, 1973.
Suen JY, Richman SP, Livingston RB, et al.: Results of BCG adjuvant immunotherapy in 100 patients with epidermoid carcinoma of the head and neck. Am J Surg 134:474–478, 1979.
Woods JE, De Santo LW, Ritts RE: A controlled study of combined methotrexate, BCG and INH therapy for squamous cell carcinoma of the head and neck. Surg Clin North Am 57:769–778, 1977.
Donaldson RC, Banda F, Kuhn R: Methotrexate plus MER for head and neck cancer. In: Crispen RG (ed) Neoplasm immunity solid tumor therapy. Philadelphia, Franklin Institute, 1977, pp 243–248.
Khandikar JD, De Wys WD: Chemoimmu-notherapy of head and neck cancer. Am J Surg 135:688–695, 1978.
Papac R, Minor DR, Rudnick S, et al.: Controlled trial of methotrexate and bacillus Cal-mette-Guerin therapy for advanced head and neck cancer. Cancer Res 38:3150–3153, 1978.
Olkowski ZL, Maren JR, Skeen MJ: Effects of combined immunotherapy with levamisole and bacillus Calmette-Guerin on immuno-competence of patients with squamous cell carcinoma of the cervix, head and neck, and lung undergoing radiation therapy. Cancer Treat Rep 62:1651–1661, 1978.
Buechler M, Mukherji B, Chasin W, Nathanson L: High dose methotrexate with and without BCG therapy in advanced head and neck malignancy. Cancer 43:1095–1100, 1979.
Perlin E: Immunotherapy in patients with oral and malignant disease. Otolaryngol Clin North Am 12:195–199, 1979.
Amiel JL, Sancho-Garnier H, Vandenbrouk C, et al.: First results of a randomized trial on immunotherapy of head and neck tumors. Recent Results Cancer Res 68:318–323, 1979.
Zbar B, Conti G, Rapp HJ, et al.: Regression of established oral tumors after intralesional injection of living BCG cell walls. Cancer 43:1304–1307, 1979.
Cheng VST, Suit HD, Wang CC, et al.: Clinical trial of Cory neb acterium pavrum (intra-lymph node and intravenous) and radiation therapy in the treatment of head and neck carcinoma. Cancer 49:235–244, 1982.
Vogl SE, Schoenfeld DA, Kaplan BH, et al.: Methotrexate alone or with regional subcutaneous Cory neb acterium pavrum in the treatment of recurrent and metastatic squamous cancer of the head and neck. Cancer 260:2295–2300, 1982.
Lundy J, Wanebo H, Pinsky C, et al.: Delayed hypersensitivity reactions in patients with squamous cell cancer of the head and neck. Am J Surg 128:530–533, 1974.
Eilber FR, Morton DL, Ketcham AS: Immunologic abnormalities in head and neck cancer. Am J Cancer 128:534–538, 1974.
Jenkins VK, Roy P, Ellis HN, et al.: Lymphocyte response in patients with head and neck cancer. Arch Otolaryngol 102:596–600, 1976.
Berenyi MR, Straus B, Avila R: T-rosettes in alcoholic cirrhosis of the liver. JAMA 232:44–46, 1975.
Law DK, Dudrick SJ, Afdon NI: Immuno-competence of patients with protein-calorie malnutrition. Ann Intern Med 79:545–550, 1973.
Silverman NA, Potvin C, Alexander JC, Chretien PB: In vitro lymphocyte reactivity and T-cell levels in chronic cigarette smokers. Clin Exp Immunol 22:285–292, 1975.
Humphrey LJ, Rush BF: Chemotherapy for tumors of the chest wall and base of neck by arterial infusion. Arch Surg 96:810–813, 1968.
Couture J: Intra-arterial infusion therapy for oral cancer. Can J Surg 11:420–423, 1968.
Dhawan IK, Rao BNB, Kapur BML, Iyer N, Chari PS: A clinical, histological and histochem-ical study of intraarterial infusion chemotherapy in oral cancer. Indian J Med Res 59:1835–1840, 1971.
Donegan WL, Harris HS: Factors influencing the success of arterial infusion chemotherapy for cancer of the head and neck. Am J Surg 123:549–559, 1972.
Freckman HA: Results in 169 patients with cancer of the head and neck treated by intraarterial infusion therapy. Am J Surg 124:501–509, 1972.
Sealy R, Helman P: Treatment of head and neck cancer with intra-arterial cytotoxic drugs and radiotherapy. Cancer 30:187–189, 1972.
Huntington MC, Du Priest RW, Fletcher WS: Intra-arterial bleomycin therapy in inoperable squamous cell carcinomas. Cancer 31:153–158, 1973.
Sealy R, Helman P, Greenstein A, Shipstone B: The treatment of locally advanced cancer of the head and neck with intra-arterial cytotoxicities, cobalt, and hyperbaric oxygen therapy. Cancer 34:497–500, 1974.
Richard JM, Sancho H, Lepintre Y, Rodary J, Pierquin B: Intra-arterial methotrexate chemotherapy and telecobalt therapy in cancer of the oral cavity and oropharynx. Cancer 34:491–496, 1974.
Donegan WC, Harris P: Regional chemotherapy with combined drugs in cancer of the head and neck. Cancer 38:1479–1483, 1976.
Busse JM, Goffinet DR, Bagshaw MA: Late local recurrences in patients with head and neck cancer treated by irradiation and intra-arterial infusion. Int J Radiat Oncol Biol Phys 1:839–848, 1976.
Auersperg M, Furlan L, Marolt F, Jarels B: Intra-arterial chemotherapy and radiotherapy in locally advanced cancer of the oral cavity and oropharynx. Int J Radiat Oncol Biol Phys 4:273–277, 1978.
Andersson T, Andreasson L, Biorklund A, Brismar J, Einer A, Eneroth CM, Hellekaut C, Landberg T, Mattison W: Intra-arterial chemotherapy of malignant head and neck tumors with superselective angiographic technique. Acta Otolaryngol [Suppl] 360:167–170, 1979.
Hollman K, Jesch W, Kuehboack J, Dimo-poulos J: Combined intra-arterial chemotherapy and radiation therapy of tumors in the maxillofacial region. J Maxillofac Surg 7:191–197, 1979.
Baker SR, Ensminger WD, Niederhuber JE: Intra-arterial infusion chemotherapy for head and neck cancer using a totally implantable infusion pump. Head Neck Surg 4:118–124, 1981.
Stephens FO, Harker GJS, Hambly CK: Treatment of advanced cancer of the lower lip in the use of intra-arterial or intravenous chemotherapy as basal treatment. Cancer 48:1309–1314, 1981.
Mika H: Remission rates of advanced squamous cell carcinoma of the oral cavity and oropharynx after intra-arterial poly-chemotherapy with vincristine, methotrexate, bleomycin and cisplatin (VMBP). Laryngol Rhinol Otol 61:520–523, 1982.
Matras H, Burkle K, Watzek G, Kuhbock J, Potzi P, Dimopoulos J: Concept of cytostatic theapy in advanced tumors of the head and neck. J Maxillofac Surg 7:150–154, 1979.
Clifford P, O’Connor AD, Durden-Smith J, et al.: Synchronous multiple drug chemotherapy and radiotherapy for advanced (stage III and IV) squamous carcinoma of the head and neck. Antibiot Chemother 24:60–72, 1978.
O’Connor D, Clifford P, Edwards WG, Dalley VM, Durden-Smith J, Hollis BA, Caiman FM: Long-term results of VBM and radiotherapy in advanced head and neck cancer. Int J Radiat Oncol Biol Phys 8:1525–1531, 1982.
Bezwoda WR, De Moor NG, Derman DP: Treatment of advanced head and neck cancer by means of radiation therapy plus chemotherapy: a randomized trial. Med Pediatr Oncol 6:353–350, 1979.
Malaker K, Robson F, Schipper H: Combined modalities in the management of advanced head and neck cancers. J Otolaryngol 9:24–30, 1980.
Marcial VA, Velez-Garcia E, Figueroa-Vallis NR, et al.: Multi-drug chemotherapy (vincristine-bleomycin-methotrexate) followed by radiotherapy in inoperable carcinomas of the head and neck. Int J Radiat Oncol Biol Phys 6:717–721, 1980.
Smith BL, Franz JL, Mira JG, Gates GA, Sarp J, Cruz AB Jr: Simultaneous combination radiotherapy and multi-drug chemotherapy for stage III and stage IV squamous cell carcinoma of the head and neck. J Surg Oncol 15:91–98, 1980.
Sinclair WK: Hydroxyurea: differential lethal effects on cultured mammalian cells during the cell cycle. Science 150:1729–1731, 1965.
Young CW, Hodas S: Hydroxyurea: inhibitory effect of DNA metabolism. Science 146:1172–1174, 1964.
Richards GJ, Chambers RG: Hydroxyurea: a radiosensitizer in the treatment of neoplasms of the head and neck. Am J Roentgenol Radium Ther Nucl Med 105:55–565, 1969.
Richards GJ, Chambers RG: Hydroxyurea in the treatment of neoplasms of the head and neck. Am J Surg 126:513–518, 1973.
Stefani S, Sells RW, Abbate J: Hydroxyurea and radiotherapy in head and neck cancer. Radiology 101:391–396, 1971.
Hussey DH, Samuels ML: Combined hydroxyurea and radiotherapy: a new dosage schedule. South Med J 65:137–141, 1972.
Lerner HJ: Concomitant hydroxyurea and irradiation: clinical experience with 100 patients with advanced head and neck cancer at Pennsylvania Hospital. Am J Surg 134:505–509, 1977.
Rominger CJ: Hydroxyurea and radiation therapy in advanced neoplasms of the head and neck. AJR 111:103–108 1971.
Phillips FS, Sternberg SS, Schwartz HS, et al.: Hydroxyurea. I. Acute cell death in proliferating tissues in rats. Cancer Res 27:61–74, 1967.
Sinclair WK: Hydroxyurea revisited: a decade of clinical studies. Int J Radiat Oncol Biol Phys 7:631–637, 1981.
Fazekos JT, Sommer C, Kramer S: Adjuvant intravenous methotrexate or definitive radiotherapy alone for advanced squamous cancers of the oral cavity, oropharynx, supraglottic larynx or hypopharynx: concluding report of an RTOG randomized trail on 638 patients. Int J Radiat Oncol Biol Phys 6:533–541, 1980.
Fazekos JT, Sommer C, Kramer S: Tumor regression and other prognosticators in advanced head and neck cancers. Int J Radiat Oncol Biol Phys 9:957–964, 1983.
Friedman M, De Nervais FN, Daly JF: Treatment of squamous cell carcinoma of the head and neck with combined methotrexate and irradiation. Cancer 26:711–721, 1970.
Lustig RA, De Mare PA, Kramer S: Adjuvant methotrexate in the radiotherapeutic management of advanced tumors of the head and neck. Cancer 37:2703–2708, 1976.
Taylor SG IV, Bytell DE, De Wys WD, et al.: Adjuvant methotrexate and leucovorin in head and neck squamous cancer. Arch Otolaryngol 104:647–651, 1978.
Kirkwood JM, Miller D, Pitman S, et al.: Initial high dose methotrexate-leucovorin (MTX-LV) in advanced squamous carcinoma of the head and neck. Proc ASCO 19:398, 1978.
Knowlton AH, Percarpio B, Bobrow S, et al.: Methotrexate and radiation therapy in the treatment of advanced head and neck tumors. Radiology 116:709–712, 1975.
Kramer S: Methotrexate and radiation therapy in the treatment of advanced squamous cell carcinoma of the oral cavity, oropharynx, supraglottic larynx and hypopharynx. Can J Otolaryngol 4:213–218, 1975.
Pointon RCS, Askill CS, Hunter RD, Wilkinson PM: Treatment of advanced head and neck carcinoma with synchronous irradiation and methotrexate. Cancer Treat Rep [Suppl 1.1] 65:145–148, 1981.
Johnson RO, Kisken WA, Curreri AR: The response of squamous cell carcinoma to intraarterial infusion with 5-fluorouracil. Cancer Chemother Rep 24:29–33, 1962.
Johnson RO, Kisken WA, Curreri AR: A report upon arterial infusion with 5-fluorouracil in 100 patients. Gynecol Obstet 120:530–536, 1965.
Bagshaw MA: Possible role of potentiators in radiation therapy. Am J Roentgenol Radium Ther Nucl Med 85:822–833, 1961.
Heidelberger C, Griesbach L, Montag BJ, et al.: Studies on fluorinated pyrimidines. II. Effects on transplanted tumors. Cancer Chemother Rep 18:305–307, 1985.
Vermund H, Hodgett J, Ansfield FJ: Effects of combined roentgen irradiation and chemotherapy on transplanted tumors in mice. Am J Roentgenol Radium Ther Nucl Med 85:559–567, 1961.
Lawton RL, Latouretter HB, Collier RG: Simultaneous high-energy irradiation and chemotherapy. Arch Surg 91:155–160, 1965.
Gollin FF, Johnson RO: Pre-irradiation 5-fluorouracil infusion in advanced head and neck carcinomas. Cancer 27:768–770, 1971.
Lo TCM, Wiley AL Jr, Ansfield FJ, et al.: Combined radiation therapy and 5-fluorouracil for advanced squamous cell carcinoma of the oral cavity and oropharynx: a randomized study. Am J Surg 126:229–235, 1976.
Terasima T, Umezowa H: Lethal effect of bleomycin on cultured mammalian cells. J Anti-biot 23:300–304, 1970.
Terasima T, Yasukawa M, Umazawa H: Breaks and rejoining of DNA in cultured mammalian cells treated with bleomycin. Gann 61:513–516, 1970.
Jorgensen SJ: Time-dose relationships in combined bleomycin treatment and radiotherapy. Eur J Cancer 8:531–534, 1972.
Hansen HS, Rygard J, Engelholm SA: Clinical use of combined bleomycin and radiation therapy for head and neck tumors and testicular cancers. Bull Cancer 68:371–378, 1976.
Shanta V, Krishnamurthi S: Combined therapy of oral cancer, bleomycin and radiation: a clinical trial. Clin Radiol 28:427–429, 1977.
Shah PM, Shukla SN, Patel KM, et al.: Effect of bleomycin radiotherapy combination in management of head and neck squamous cell carcinoma. Cancer 48:1106–1109, 1981.
Kapstad B: Cobalt and bleomycin against carcinomas of head and neck: a controlled clinical study. Acta Otolaryngol [Suppl] 360:171–173, 1979.
Seagren SL, Byfield JE, Nahum AM, et al.: Treatment of locally advanced squamous cell carcinoma of the head and neck with concurrent bleomycin and external beam radiation therapy. Int J Radiat Oncol Biol Phys 5:1531–1535, 1979.
Rygard J, Hansen HS: Bleomycin as adjuvant in radiation therapy of advanced squamous cell carcinoma in the head and neck. Acta Otolaryngol [Suppl] 360:161–166, 1979.
Laccoureye H, Haguet JF: Bleomycin as a complement in the treatment of pharynx and larynx carcinomas: a three-year assessment. Gann Monogr Cancer Res 19:171–175, 1976.
Berdal P: Head and neck carcinoma: treatment with bleomycin and radiation. Gann Monogr Cancer Res 19:133–3149, 1976.
Suzuki V, Miyaki H, Saka M: Bleomycin treatment of maxillary cancer and 5-year survival. Gann Monogr Cancer Res 19:151–158, 1976.
Matsumura V, Soda T, Motomura K: Combined treatment for carcinomas of the paranasal sinuses irradiation and bleomycin. Eye Ear Nose Throat Monogr 52:25–34, 1973.
Cachin Y, Jortay A, Sancho H, et al.: Preliminary results of randomized E.O.R.T.C. study comparing radiotherapy and concomitant bleomycin to radiotherapy alone in epidermoid carcinomas of the oropharynx. Eur J Cancer 13:1389–1395, 1977.
Silverberg IJ, Phillips TL, Fu KK, Chan PYM: Combined radiotherapy and bleomycin for advanced head and neck cancers: results of a phase I pilot study. Cancer Treat Rep 65:697–698, 1981.
Zak M, Drobnik J: Effect of cis-dichloro-diammineplatinum (II) on the post-irradiation lethality in mice after irradiation with x-rays. Strahlentherapie 142:112–115, 1971.
Wodinsky I, Swincarski J, Kensler CJ, Venditti JM: Combination radiotherapy and chemotherapy for P388 lymphatic leukemia in vivo. Cancer Treat Rep 4:73–97, 1974.
Richmond RC, Zimbrick JD, Hykes DL: Radiation induced DNA damage and lethality in E. coli as modified by the anti-tumor agent cis-dichlorodiammineplatinum (II). Radiat Res 71:447–460, 1977.
Douple EB, Richmond RC, Logan ME: Therapeutic potentiation in a mouse mammary tumor and an intracerebral rat brain tumor by combined treatment with cis-dichlorodiammineplatinum (II) and radiation. J Clin Hema-tol Oncol 7:585–603, 1977.
Soloway MS, Morris CR, Suderth B: Radiation therapy and cis-diamminedichloroplatinum (II) in transplantable and primary murine bladder cancer. Int J Radiat Oncol Biol Phys 5:1355–1360, 1979.
Twentyman PR, Kallman RF, Brown JM: The effect of time between x-irradiation and chemotherapy on the growth of three solid mouse tumors. III. Cis-diamminedichloroplatinum. Int J Radiat Oncol Biol Phys 5:1365–1367, 1979.
Carde P, Laval F: Effect of cis-dichlorodiammineplatinum II and x-rays on mammalian cell survival. Int J Radiat Oncol Biol Phys 7:929–933, 1981.
Overgaard J, Khan AR: Selective enhancement of radiation response in a C3H mammary carcinoma by cis-platinum. Cancer Treat Rep 65:501–503, 1981.
Szumiel I, Nias AHW: The effect of combined treatment with a platinum complex and ionizing radiation on Chinese hamster ovary cells in vitro. Br J Cancer 33:450–458, 1976.
Al-Sarraf M, Jacobs J, Kinzie J, et al.: Combined modality therapy utilizing single high intermittent dose of cis-platinum and radiation in patients with advanced head and neck cancer. Proc ASCO 2:159, 1983.
Taylor SG, Sisson GA, Bytell DE: Adjuvant chemoimmunotherapy of head and neck cancer. Recent Results Cancer Res 68:297–308, 1979.
Szpirglas H, Chastang C, Bertrand JC: Adjuvant treatment of tongue and floor of the mouth cancers. Recent Results Cancer Res 68:309–317, 1978.
Wanebo HJ, Hilal EY, Strong EW, et al: Adjuvant trial of levamisole in patients with squamous cancer of the head and neck: a preliminary report. Recent Results Cancer Res 68:324–333, 1978.
Tarpley JL, Chretien PB, Alexander JC, et al.: High dose methotrexate as a pre-operative adjuvant in the treatment of epidermoid carcinoma of the head and neck: a feasibility study and clinical trial. Am J Surg 130:147–152, 1975.
Randolph VL, Vallajo A, Spiro RH, et al.: Combination therapy of advanced head and neck cancer: induction of remissions with di-amminedichloroplatinum (II), bleomycin, and radiation therapy. Cancer 41:460–467, 1978.
Arlen M: Combined radiation methotrexate therapy in preoperative management of cancer of the head and neck. Am J Surg 132:536–540, 1976.
Carter SK: The chemotherapy of head and neck cancer. Semin Oncol 4:413–424, 1977.
Hande KR, Chretien PB, Elias EG, et al: Thirty-six hour preoperative high-dose methotrexate infusion in patients with squamous carcinoma of the head and neck. Med Pediatr Oncol 6:39–45, 1979.
Hong WK, Shapshay SM, Bhutani R, et al.: Induction chemotherapy in advanced squamous head and neck carcinoma with high-dose cis-platinum and bleomycin infusion. Cancer 44:19–25, 1979.
Kloss R, Oster M, Blitzer A, et al.: Cis-platinum (P) and bleomycin (B) for previously untreated locally advanced squamous cell carcinoma of the head and neck. Proc ASCO 22:535, 1981.
Glick JH, Marcial V, Richter M, et al.: The adjuvant treatment of inoperable stage III and IV epidermoid carcinoma of the head and neck with platinum and bleomycin infusions prior to definitive radiotherapy: an RTOG pilot study. Cancer 46:1919–1924, 1980.
Al-Sarraf M, Amer MH, Vaishampayan G, et al.: A multi-disciplinary therapeutic approach for advanced previously untreated epidermoid cancer of the head and neck: preliminary report. Int J Radiat Oncol Biol Phys 5:1421–1423, 1979.
Wittes R, Heller K, Randolph V, et al.: Cis-dichlorodiammineplatinum (Il)-based chemotherapy as initial treatment of advanced head and neck cancer. Cancer Treat Rep 63:1533–1538, 1979.
Brown AW, Blom J, Butler WM, et al: Combination chemotherapy with vinblastine, bleomycin, and cis-diamminedichloroplatinum (II) in squamous cell carcinoma of the head and neck. Cancer 45:2830–2835, 1980.
Schuller DE, King GW, Smithe RE, et al.: Combination therapy protocol for stage III or IV carcinoma of the oral cavity, oropharynx, and hypopharynx. Laryngoscope 90:1263–1272, 1980.
Peppard SB, Al-Sarraf M, Powers WE, et al.: Combination of cis-platinum, Oncovin, and bleomycin (COB) prior to surgery and/or radiotherapy in advanced untreated epidermoid cancer of the head and neck. Laryngoscope 90:1273–1280, 1980.
Spaulding MB, Klotch D, Grillo J, et al.: Adjuvant chemotherapy in the treatment of advanced tumors of the head and neck. Am J Surg 140:538–542, 1980.
Weaver A, Loh JJ-K, Vandenberg H, et al.: Combined modality therapy of advanced head and neck cancer. Am J Surg 140:549–552, 1980.
Al-Sarraf M, Drelichman A, Jacobs J, et al.: Adjuvant chemotherapy with cis-platinum, Oncovin, and bleomycin followed by surgery and/or radiotherapy in patients with advanced previously untreated head and neck cancer: final report. In: Jones SE, Salmon SE (eds) Adjuvant therapy of cancer III. New York, Grune and Stratton, 1981, pp 145–152.
Hong WK, Shapshay SM: Treatment of previously untreated stage III and IV squamous cell carcinoma of the head and neck. Otolaryngol Clin North Am 13:521–528, 1980.
Pennacchio JL, Hong WK, Shapshay S, et al.: Combination of cis-platinum and bleomycin prior to surgery and/or radiotherapy compared with radiotherapy alone for the treatment of advanced squamous cell carcinoma of the head and neck. Cancer 50:2795–2801, 1982.
Schuller DE, Wilson HE, Smith RE, Batley F, James AD: Pre-operative reductive chemotherapy for locally advanced carcinoma of the oral cavity, oropharynx, and hypopharynx. Cancer 51:15–19, 1983.
Spaulding MB, Kahn A, De Los Santos R, Klotch D, Lore JH Jr: Adjuvant chemotherapy in advanced head and neck cancer: an update. Am J Surg 144:432–436, 1982.
Tannock I: Cummings B, Sorrenti V, ENT Group: Combination chemotherapy prior to radiation therapy for locally advanced squamous cell carcinoma of the head and neck. Cancer Treat Rep 66:1421–1424, 1982.
Vogl SE, Lerner H, Kaplan BH, Caughlin C, Mormick B, Camacho F, Cinberg J: Failure of effective initial chemotherapy to modify the course of stage IV (Mo) squamous cancer of the head and neck. Cancer 50:840–847, 1982.
Seifert P, Baker L, Reed M, Vaitkevicius VK: Comparison of continuously infused 5-fluorouracil with bolus injection in the treatment of patients with colo-rectal adenocarcinoma. Cancer 36:123–128, 1975.
Ervin TJ, Kirkwood J, Weichselbaum RP, et al.: Improved survival for patients with advanced carcinoma of the head and neck treated with methotrexate-leucovorin prior to definitive radiotherapy or surgery. Laryngoscope 91: 1181–1190, 1981.
Al-Sarraf M, Drelichman A, Peppard S, et al.: Adjuvant cisplatinum and 5-fluorouracil 96-hour infusion in previously untreated epidermoid cancers of the head and neck. Proc ASCO 22:428, 1981.
Kish J, Drelichman A, Jacobs J, et al.: Clinical trial of cis-platinum and 5-fluorouracil as initial treatment for advanced squamous cell carcinoma of the head and neck. Cancer Treat Rep 66:471–474, 1982.
Decker DA, Drelichman A, Jacobs J, et al.: Adjuvant chemotherapy with cis-diammine-dichloroplatinum II and 120 hour infusion 5-fluorouracil in stage III and IV squamous cell carcinoma of the head and neck. Cancer 51: 1353–1355, 1983.
Weaver A, Fleming S, Vandenberg H, et al.: Cis-platinum and 5-fluorouracil as initial therapy in advanced epidermoid cancer of the head and neck. Head Neck Surg 4:370–373, 1982.
Decker DA, Drelichman A, Jacobs J, et al.: Adjuvant chemotherapy with high dose bolus cis-diamminedichloroplatinum II (CCD) and 120-hour infusion of 5-fluorouracil (5FU) in stage III and IV squamous cell carcinoma of the head and neck. Proc ASCO 1:195, 1982.
Weaver A, Fleming S, Kish J, et al.: Cis-platinum and 5-fluorouracil as induction therapy for advanced head and neck cancer. Am J Surg 144:445–448, 1982.
Gale GR, Atkins LM, Meischen SJ, et al.: Combination chemotherapy of LI210 leukemia with platinum compounds and cyclophosphamide plus other selected antineoplastic agents. JNCI 57:1363–1366, 1976.
Gale GR, Atkins LM, Meischen SJ, et al.: Chemotherapy of advanced LI210 leukemia with platinum compounds in combination with other anti-tumor agents. Cancer Treat Rep 61:445–450, 1977.
Speer RJ, Lapis S, Ridgway H, et al.: Cis-platinum diamminodichloride (PDD) in combination therapy of leukemia LI210. Wesley Med Bull 1:103–109, 1971.
Woodman RJ, Sirica AE, Gang M, et al.: The enhanced therapeutic effects of cis-platinum (II) diamminedichloride against L1210 leukemia when combined with cyclophosphamide or 1, 2-bis (3, 5-dioxopiperazine-l-yl)-propane or several other anti-tumor agents. Chemotherapy 18:169–183, 1973.
Kline I: Potentially useful combinations of chemotherapy detected in mouse tumor systems. Cancer Chemother Rep [Part 2] 41:3343, 1974.
Schabel FM Jr, Trader MW, Laster WR Jr, et al.: Cis-dichlorodiamminoplatinum (II): combination chemotherapy and cross-resistance studies with tumors of mice. Cancer Treat Rep 63:1459–1473, 1979.
Baker SR, Makuch RW, Wolf GT: Preoperative cis-platinum (DDP) and bleomycin (BLM) in patients with head and neck squamous cell carcinoma (HNSCC): prognostic factors for tumor response. The head and neck contracts program. Arch Otolaryngol 101: 683–689, 1981.
Schuller DE, King GW, Smith RE, et al.: Cis-platinum, methotrexate, bleomycin, and vincristine pre-operative chemotherapy. Head Neck Surg 3:262, 1981.
Kish J, Drelichman A, Weaver A, et al.: Cis-platinum and 5-fluorouracil infusion in patients with recurrent and disseminated epidermoid cancer of the head and neck. Proc ASCO 1:193, 1982.
Al-Sarraf M, Kinzie J, Jacobs J, et al.: New way of giving chemotherapy as part of multi-disciplinary treatment for patients with head and neck cancer: preliminary report. Proc AACR 23:134, 1982.
Ensley J, Jacobs J, Weaver A, et al.: Initial cis-platinum combination predicting response to radiotherapy in patients with advanced epidermoid cancers of the head and neck. Proc ASCO 1:197, 1982.
Fu KK, Leibel SA, Levine ML, Freidlander LM, Boles R, Phillips TL: Cancer of the major and minor salivary glands: analysis of pretreat-ment results and sites and causes of failure. Cancer 40:2882–2890, 1977.
Reutschler R, Burges M, Byers R: Chemotherapy of malignant major salivary gland neoplasms: a 25 year review of M.D. Anderson Hospital Experiences. Cancer 40:619–624, 1977.
Suen JY, Johns ME: Chemotherapy for salivary gland cancer. Larynogoscope 92:235–239, 1982.
Posner MR, Ervin TJ, Weichselbaum RR, Fabian RL, Miller D: Chemotherapy of advanced salivary gland neoplasms. Cancer 50: 2261–2264, 1982.
Alberts DS, Manning MR, Coulthard SW, Koopmann CF, Herman TS: Adriamycin/ cisplatinum/cyclophosphamide combination chemotherapy for advanced carcinoma of the parotid gland. Cancer 47:645–648, 1981.
Tannock IF, Southerland DJ: Chemotherapy for adenoid cystic carcinoma. Cancer 46:452–454, 1980.
Schramm VL Jr, Srodes C, Myers EH: Cispla-tin therapy for adenoid cystic carcinoma. Arch Otolaryngol 107:739–741, 1981.
Skibba JL, Hurley JD, Ravela HC: Complete response of a metastatic adenoid cystic carcinoma of the parotid gland to chemotherapy. Cancer 47:2543–2548, 1981.
Vermeer RJ, Pinedo HM: Partial remission of advanced adenoid cystic carcinoma obtained with adriamycin. Cancer 43:1604–1606, 1979.
Johnson RO, Lang RD, Kisken WA, Curreri AR: Infusion of 5-fluorouracil in cylindroma treatment. Arch Otolaryngol 79:625–627, 1964.
Budd GT, Groppa CW: Adenoid cystic carcinoma of the salivary gland: sustained complete response to chemotherapy. Cancer 51:589–590, 1983.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1986 Martinus Nijhoff Publishing, Boston
About this chapter
Cite this chapter
Al-Sarraf, M. (1986). Chemotherapeutic Management of Head and Neck Neoplasia. In: Peterson, D.E., Elias, E.G., Sonis, S.T. (eds) Head and Neck Management of the Cancer Patient. Developments in Oncology, vol 36. Springer, Boston, MA. https://doi.org/10.1007/978-1-4613-2289-4_17
Download citation
DOI: https://doi.org/10.1007/978-1-4613-2289-4_17
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4612-9411-5
Online ISBN: 978-1-4613-2289-4
eBook Packages: Springer Book Archive